Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients

BACKGROUND: Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER 2) and inhibits carcinoma cellular proliferation. Its use as an adjuvant for a period of one year is currently an internationally recognised standard...

Descripción completa

Detalles Bibliográficos
Autores principales: Aitelhaj, Meryem, LKhouyaali, Siham, Rais, Ghizlane, Mohtaram, Amina, Raissouni, Soundouss, Ghissassi, Brahim, Boutayeb, Saber, Mrabti, Hind, Bensouda, Youssef, Errihani, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765764/
https://www.ncbi.nlm.nih.gov/pubmed/23985308
http://dx.doi.org/10.1186/1756-0500-6-339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765764/
https://www.ncbi.nlm.nih.gov/pubmed/23985308
http://dx.doi.org/10.1186/1756-0500-6-339

Ejemplares similares